Search

IAS 2027, the 14th IAS Conference on HIV Science

AIDS 2026, the 26th International AIDS Conference

Roundup: Must-Read Conversations and Resources from the Last Week 

Last week marked one year since the US president took office and began systematically dismantling global health and equity. Here is a roundup of essential conversations and resources summarizing the past 365 days and what’s at stake as we move forward.

AVAC Calls for the Immediate Rejection of the Global Gag Rule and Any Expansion of it

AVAC calls for the immediate rejection of the Global Gag Rule and any expansion of it and urges US lawmakers to uphold science, human rights, and public health.

AVAC Calls for the Immediate Rejection of the Global Gag Rule and Any Expansion of it

AVAC calls for the immediate rejection of the Global Gag Rule and any expansion of it and urges US lawmakers to uphold science, human rights, and public health.

Global Health Watch: Reflecting on 1 Year of Chaos and What’s Next, Congress Pushes Back, the Future of WHO, US Undermines African Authority

This week marks 365 days of disruption and chaos across global health, with many organizations and journalists reflecting on one year after the foreign aid freeze and what the future of global health looks like. We are also watching closely for news of an expanded Global Gag Rule.

One Year Later

This week marks one year since the US Presidential Administration issued a deeply cruel executive order freezing foreign assistance. To mark this moment, AVAC’s One Year Later series reflects on the impact of the past 365 days on five key areas of global health and development

One Year Later #5: Rethinking & Rebuilding Global Health

As we wrap up our ‘One Year Later’ series, in this fifth installment, we look to the future and what is built next. Champions of global health must define the architecture of the future, or it will be written by people bent on dismantling it.

One Year Later #4: The Cruel Irony of Lenacapavir for PrEP

In the fourth installment of our ‘One Year Later’ series we focus on lenacapavir and how science is breaking through formidable barriers in understanding HIV and how to prevent it, just as the infrastructure for delivering groundbreaking technology is defunded and destabilized.

EXPrESSIVE Phase 3 Trials Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.